Skip to content

Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients

Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients With Domiciliary Follow-up

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04802018
Acronym
SOY+
Enrollment
300
Registered
2021-03-17
Start date
2021-03-09
Completion date
2022-12-28
Last updated
2023-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Telemedicine, COVID-19, wearable device, e-Health, Remote monitoring

Brief summary

The aim of the study is to provide clinical decision support to healthcare professionals using a wearable for non-invasive multimodal monitoring, allowing early detection of disease progression to severe forms, as well as the detection of significant clinical events. For the development of the study, 500 individuals with COVID-19 in home confinement will be randomly assigned to form part of the control group, which will be followed conventionally by Primary Care Professionals, or to the experimental group, which will also be provided with the wearable device for non-invasive multimodal monitoring linked to an App for transfering data. Furthermore, the patient will be able to interact with the application on three times daily by indicating the symptoms contemplated and answering the decision clinical questions. In this way, alarms can be generated in the presence of symptoms or significant alterations in the parameters monitored by the device, which the health professionals of the Primary Care teams included in the study will evaluate at the appropriate time, taking the best decision in each case.

Detailed description

As variables to be considered in order to compare the effectiveness of the system against the conventional monitoring protocol, complemented with real-time patient notification of symptoms, certain variables will be collected, such as: Baseline variables: * Age, sex, date of COVID-19 positive diagnosis (PCR or antigen test). * Stage of clinical progression of the disease: according to the Primary Care COVID-19 management * Information collected in the telephone clinical assessment questionnaire in the home follow-up of the patient with SARS-CoV-2 infection Variables generated by the study follow-up: * Vital signs covered by the Bakeey E66 smartwatch device: temperature, respiration rate (RR), heart rate (HR) and oxygen saturation (SatO2) * Clinical symptoms covered by the Home App for submission by the patient: cough, fever, chest pain, respiratory distress (dyspnoea), vomiting and diarrhoea.

Interventions

DEVICEClinical decision support system based on non-invasive multimodal monitoring

Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.

Sponsors

Hospital Clínico Universitario de Valladolid
CollaboratorOTHER
University of Valladolid
CollaboratorOTHER
Sanidad de Castilla y León
CollaboratorOTHER
Increase-Tech
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Single-blind, controlled, randomised clinical trial

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Confirmed diagnosis of SARS-CoV-2 disease, detected by PCR or antigen test, performed 72 h prior to patient inclusion in the study. * Acceptance to sign the informed consent document. * Possession of a Smartphone or Tablet with Internet connection. * Possession of mental faculties to participate in the study.

Exclusion criteria

* Age below the age of health majority (16 years). * Lack of digital skills to use the Home App. * Cognitive impairment that prevents the patient from participating in the study. * Disabling pathology of the upper limb.

Design outcomes

Primary

MeasureTime frame
Evolution to severe progression of COVID-19One month after inclusion of patients in the study
Need for admission to ICU.One month after inclusion of patients in the study
Mortality rate.One month after inclusion of patients in the study

Secondary

MeasureTime frame
Need for invasive mechanical ventilationOne month after inclusion of patients in the study
Hospital admission rateOne month after inclusion of patients in the study
Economic cost of the care derived from the episode for the social and health care system.One month after inclusion of patients in the study
Occurrence of major vascular eventsOne month after inclusion of patients in the study
Delay to hospital admissionOne month after inclusion of patients in the study
Average hospital stayOne month after inclusion of patients in the study

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026